THE USAGE OF TRIMETAZIDINE AND SULODEXIL TO PREVENT TRANSFORMATION OF A NON-Q MI INTO A Q-MI
Abstract
In main group 104 patients of Q-myocardial infarction were treated during the first 7 days of the moment it entered a hospital by trimetazidine and sulodexide combine with the traditional treatment (nytroconnection, aspirin, beta- adrenoblocators). In control group 130 patients were treated only by traditional treatments. The blood of 62 patients from main group and 65 patients from control group was examined on thrombin’s time, partly activated tromboplastine’s time and thrombocite aggregation in dynamics three times in the first, the third and the 7-th days of observation. There were undergoing daily ECG-monitoring on Cholter. The results of treatments were valued in both groups according the number of patients with Q-myocardial infarction, average daily frequency of attacks angina pectoris, the number and duration of episodes painless myocardial ishemic, changes of parameter of hemostasis. It was exposed, that in main group Q-myocardial infarction was developed only in 2,9% patients and in 14,6% patients in control group. The average daily frequency of attacks of angina pectoris, the number of episodes of painless myocardial ishemic and their duration in main group were nearly 2 times less them in control group. It was accompanied by improvement hemostasis in main group. Thus, trimetazidine and sulodexide promote the prophylaxis Q-myocardial infarction.
About the Authors
A. A. Abdullaev
Дагестанская государственная медицинская академия, Махачкала;
РГМУ
Russian Federation
Russian Federation
U. A. Islamova
Дагестанская государственная медицинская академия, Махачкала;
РГМУ
Russian Federation
Russian Federation
R. M. Gafurova
Дагестанская государственная медицинская академия, Махачкала;
РГМУ
Russian Federation
Russian Federation
References
1. Алмазов В.А., Шляхто Е.В., Нифонтова Е.М., Вахрамеева И.В. и соавт. Антиишемическая эффективность триметазидина у больных со стабильной стенокардией. // Кардиология, 2000; №6, стр.40-42.
2. Аронов Д.М., Васильева Е.Ю., Зыкова В.П., Аврусин К.Е. и соавт. Влияние низкомолекулярного гепарина (сулодексида) на показатели гемостаза у больных с нестабильной стенокардией. // Кардиология, том 34; 1994; № 7, стр. 21-27.
3. Аронов Д.М., Бубнова М.Г., Зыкова В.П., Васильева Е.Ю. Значение сулодексида – низкомолекулярного гепарина – во вторичной профилактике ишемической болезни сердца. // Кардиология, 1995; №11, стр. 24-29.
4. Грацианский Н.А., Явелов И.С., Покровская Е.В. (попоручению группы исследователей, Россия). Эноксапарин при нестабильной стенокардии и инфаркте миокарда без зубца Q: результаты многоцентрового исследования в России. // Кардиология, 2000; №4, стр. 4-14.
5. Евсиков Е.М. Низкомолекулярный гепарин - клексан в лечении острого коронарного синдрома у больных с тяжелым течением ишемической болезни сердца. // Российский кардиологический журнал, 1999; №5, стр.31-35.
6. Люсов В.А., Белоусов Ю.Б., Савенков М.П. К методу определения агрегации тромбоцитов и эритроцитов. // Лабор. дело.- 1976.- №8.- Стр.463-466.
7. Brottier L., Barat J.L., Combe C., Boussens B. е. а. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. // Eur. Heart J., 1990; 11: 207-12.
8. Hoover R., Rosenberg R. e. a. Inhibition rot arterial smooth muscle cell prolifaration by heparin. // Circulat. Res. –1980. – 47. – 578-583.
9. Kiss J. Chemical structure of heparin. // New York. – 1976. – 1-17.
10. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.L. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. // Cardiovasc. Res., 1997; 33: 243-257.
11. Lu C., Dabrowski P., Fragasso G., Cherchia S.L. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. // Am. J. Cardiol., v. 82, p. 898-901.
12. Renaud J.F. Internal. ph. Na+ and Ca2+ regulation by trimetazidine during cardiac cell acidosis. // Cardiovasc. Drugs. Ther., 1988; 1: 677-86.
13. Shimotori F., Sakuzagawa N. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II and antithrombin III affinity between low molecular weight heparin and unfractionated heparin. // Thromb. Hemostas., 1990; 6: 71.
Review
For citations:
Abdullaev A.A., Islamova U.A., Gafurova R.M. THE USAGE OF TRIMETAZIDINE AND SULODEXIL TO PREVENT TRANSFORMATION OF A NON-Q MI INTO A Q-MI. Russian Journal of Cardiology. 2001;(5):38-40. (In Russ.)
Views:
706
Email this article 